Effectiveness of Whole-Virus COVID-19 Vaccine among Healthcare Personnel, Lima, Peru

Carmen Sofia Arriola; Giselle Soto; Matthew Westercamp; Susan Bollinger; Angelica Espinoza; Max Grogl; Alejandro Llanos-Cuentas; Eduardo Matos; Candice Romero; Maria Silva; Rachel Smith; Natalie Olson; Michael Prouty; Eduardo Azziz-Baumgartner; Fernanda C. Lessa

doi:10.3201/EID2813.212477

Effectiveness of Whole-Virus COVID-19 Vaccine among Healthcare Personnel, Lima, Peru

Carmen Sofia Arriola
, Giselle Soto
, Matthew Westercamp
, Susan Bollinger
, Angelica Espinoza
, Max Grogl
, Alejandro Llanos-Cuentas
, Eduardo Matos
, Candice Romero
, Maria Silva
, Rachel Smith
, Natalie Olson
, Michael Prouty
, Eduardo Azziz-Baumgartner
, Fernanda C. Lessa

Centers for Disease Control and Prevention
NAMRID-Unit 3800
Hospital Nacional Cayetano Heredia
Arzobispo Loayza Hospital

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

In February 2021, Peru launched a COVID-19 vaccination campaign among healthcare personnel using an inactivated whole-virus vaccine. The manufacturer recommended 2 vaccine doses 21 days apart. We evaluated vaccine effectiveness among an existing multiyear influenza vaccine cohort at 2 hospitals in Lima. We analyzed data on 290 participants followed during February-May 2021. Participants completed a baseline questionnaire and provided weekly self-collected nasal swab samples; samples were tested by real-time reverse transcription PCR. Median participant follow-up was 2 (range 1-11) weeks. We performed multivariable logistic regression and adjusted for preselected characteristics. During the study, 25 (9%) participants tested SARS-CoV-2-positive. We estimated adjusted vaccine effectiveness at 95% (95% CI 70%-99%) among fully vaccinated participants and 100% (95% CI 88%-100%) among partially vaccinated participants. These data can inform the use and acceptance of inactivated whole-virus vaccine and support vaccination efforts in the region.

Original language	English
Pages (from-to)	S238-S243
Journal	Emerging Infectious Diseases
Volume	28
Issue number	13
DOIs	https://doi.org/10.3201/EID2813.212477
State	Published - Dec 2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.3201/EID2813.212477

Cite this

Arriola, C. S., Soto, G., Westercamp, M., Bollinger, S., Espinoza, A., Grogl, M., Llanos-Cuentas, A., Matos, E., Romero, C., Silva, M., Smith, R., Olson, N., Prouty, M., Azziz-Baumgartner, E., & Lessa, F. C. (2022). Effectiveness of Whole-Virus COVID-19 Vaccine among Healthcare Personnel, Lima, Peru. Emerging Infectious Diseases, 28(13), S238-S243. https://doi.org/10.3201/EID2813.212477

@article{66d32a9715dc47c5a9fc4a8e04181cba,

title = "Effectiveness of Whole-Virus COVID-19 Vaccine among Healthcare Personnel, Lima, Peru",

abstract = "In February 2021, Peru launched a COVID-19 vaccination campaign among healthcare personnel using an inactivated whole-virus vaccine. The manufacturer recommended 2 vaccine doses 21 days apart. We evaluated vaccine effectiveness among an existing multiyear influenza vaccine cohort at 2 hospitals in Lima. We analyzed data on 290 participants followed during February-May 2021. Participants completed a baseline questionnaire and provided weekly self-collected nasal swab samples; samples were tested by real-time reverse transcription PCR. Median participant follow-up was 2 (range 1-11) weeks. We performed multivariable logistic regression and adjusted for preselected characteristics. During the study, 25 (9\%) participants tested SARS-CoV-2-positive. We estimated adjusted vaccine effectiveness at 95\% (95\% CI 70\%-99\%) among fully vaccinated participants and 100\% (95\% CI 88\%-100\%) among partially vaccinated participants. These data can inform the use and acceptance of inactivated whole-virus vaccine and support vaccination efforts in the region.",

author = "Arriola, \{Carmen Sofia\} and Giselle Soto and Matthew Westercamp and Susan Bollinger and Angelica Espinoza and Max Grogl and Alejandro Llanos-Cuentas and Eduardo Matos and Candice Romero and Maria Silva and Rachel Smith and Natalie Olson and Michael Prouty and Eduardo Azziz-Baumgartner and Lessa, \{Fernanda C.\}",

year = "2022",

month = dec,

doi = "10.3201/EID2813.212477",

language = "Ingl{\'e}s",

volume = "28",

pages = "S238--S243",

journal = "Emerging Infectious Diseases",

issn = "1080-6040",

number = "13",

}

Arriola, CS, Soto, G, Westercamp, M, Bollinger, S, Espinoza, A, Grogl, M, Llanos-Cuentas, A, Matos, E, Romero, C, Silva, M, Smith, R, Olson, N, Prouty, M, Azziz-Baumgartner, E & Lessa, FC 2022, 'Effectiveness of Whole-Virus COVID-19 Vaccine among Healthcare Personnel, Lima, Peru', Emerging Infectious Diseases, vol. 28, no. 13, pp. S238-S243. https://doi.org/10.3201/EID2813.212477

TY - JOUR

T1 - Effectiveness of Whole-Virus COVID-19 Vaccine among Healthcare Personnel, Lima, Peru

AU - Arriola, Carmen Sofia

AU - Soto, Giselle

AU - Westercamp, Matthew

AU - Bollinger, Susan

AU - Espinoza, Angelica

AU - Grogl, Max

AU - Llanos-Cuentas, Alejandro

AU - Matos, Eduardo

AU - Romero, Candice

AU - Silva, Maria

AU - Smith, Rachel

AU - Olson, Natalie

AU - Prouty, Michael

AU - Azziz-Baumgartner, Eduardo

AU - Lessa, Fernanda C.

PY - 2022/12

Y1 - 2022/12

N2 - In February 2021, Peru launched a COVID-19 vaccination campaign among healthcare personnel using an inactivated whole-virus vaccine. The manufacturer recommended 2 vaccine doses 21 days apart. We evaluated vaccine effectiveness among an existing multiyear influenza vaccine cohort at 2 hospitals in Lima. We analyzed data on 290 participants followed during February-May 2021. Participants completed a baseline questionnaire and provided weekly self-collected nasal swab samples; samples were tested by real-time reverse transcription PCR. Median participant follow-up was 2 (range 1-11) weeks. We performed multivariable logistic regression and adjusted for preselected characteristics. During the study, 25 (9%) participants tested SARS-CoV-2-positive. We estimated adjusted vaccine effectiveness at 95% (95% CI 70%-99%) among fully vaccinated participants and 100% (95% CI 88%-100%) among partially vaccinated participants. These data can inform the use and acceptance of inactivated whole-virus vaccine and support vaccination efforts in the region.

AB - In February 2021, Peru launched a COVID-19 vaccination campaign among healthcare personnel using an inactivated whole-virus vaccine. The manufacturer recommended 2 vaccine doses 21 days apart. We evaluated vaccine effectiveness among an existing multiyear influenza vaccine cohort at 2 hospitals in Lima. We analyzed data on 290 participants followed during February-May 2021. Participants completed a baseline questionnaire and provided weekly self-collected nasal swab samples; samples were tested by real-time reverse transcription PCR. Median participant follow-up was 2 (range 1-11) weeks. We performed multivariable logistic regression and adjusted for preselected characteristics. During the study, 25 (9%) participants tested SARS-CoV-2-positive. We estimated adjusted vaccine effectiveness at 95% (95% CI 70%-99%) among fully vaccinated participants and 100% (95% CI 88%-100%) among partially vaccinated participants. These data can inform the use and acceptance of inactivated whole-virus vaccine and support vaccination efforts in the region.

UR - https://www.scopus.com/pages/publications/85143917349

U2 - 10.3201/EID2813.212477

DO - 10.3201/EID2813.212477

M3 - Artículo

C2 - 36502444

AN - SCOPUS:85143917349

SN - 1080-6040

VL - 28

SP - S238-S243

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

IS - 13

ER -

Effectiveness of Whole-Virus COVID-19 Vaccine among Healthcare Personnel, Lima, Peru

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this